Other Headlines

Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.
The medical community pays tribute to a dedicated crew.
Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.
A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.
The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.

Have News for Us?

Submit your news on the industry, people, or companies.

Forward to a Friend

More Industry Headlines

House Passes Medicare Physician Payment Reform Act Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.

Clinical PET-MRI Moves Closer to Reality Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.

Aural Trumps Oral for Ear Treatment A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.

Scientists Find Unusual Immune System Activity in Brains of Schizophrenics The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.

Senate Health Care Reform Bill Unveiled Legislation may go to cloture vote this weekend. Read the details.

RSNA 2009 Preview This year's RSNA should provide a very interesting look at the effects of the economy on the major OEMs. As always, vendors are whipping up the hoopla, and inside this story are great previews of what's being debuted. But DOTmed reporters will also be there to get the real buzz. Look for video interviews in our Online News direct from the show.

Interview With Fred Robertson, President & CEO of TomoTherapy TomoTherapy president and CEO Fred Robertson talks with DOTmed about his perspective on ASTRO's 2009 annual meeting, changes in the radiation oncology industry and two important TomoTherapy product launches that occurred at the show. Watch the HD video.

Health Care Reform Round-Up: CBO Pegs Senate Bill at $849 Billion The numbers are in on the Senate's version of reform. Also read about the wide-ranging impact that the legislation would have.

Pen-Sized Microscope Aims for Precise Brain Surgeries A confocal microscope picking up brain-safe fluorescent dyes could result in more accurate and streamlined surgeries to remove tumors from the brain.

U.S. Preventive Services Task Force Has Stunning New Guidelines on Mammography Agency recommends no routine screening for women 40-49, no self-examination. Read the details.

Cardinal Health will open
three additional PET
facilities this year

Cardinal Health Expands Manufacturing Capabilities for PET Tracers

by Barbara Kram, Editor
New Orleans - Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, will open three additional Positron Emission Tomography (PET) radiopharmaceutical manufacturing facilities near its existing nuclear pharmacy locations this year.

These manufacturing facilities use cyclotrons to produce fluorine-18 (F-18), the radioactive precursor needed to create fluorodeoxyglucose (FDG), the PET imaging agent commonly used to diagnose various diseases. FDG's relatively short half-life of just under two hours makes it challenging to efficiently distribute the product over great distances.

By locating cyclotrons near its nuclear pharmacy sites, Cardinal Health is able to efficiently distribute FDG to a greater number of hospitals, clinics and research facilities using its comprehensive fleet and logistics capabilities.

The company currently operates 22 cyclotrons and distributes PET products through nearly half of its more than 150 U.S. nuclear pharmacy locations. This year Cardinal Health will open three new cyclotrons located in Tampa, FL, Hartford, CT and Louisville, KY.

In addition to FDG, the company's new cyclotrons will produce a variety of other PET imaging agents to support oncology, neurology and cardiac imaging procedures.

"Making PET technology more accessible to a greater number of facilities, clinicians and patients is critical to the continued growth of molecular imaging," said John Rademacher, general manager of specialty and nuclear pharmacy services for Cardinal Health. "By co-locating cyclotrons adjacent to select radiopharmacies within our network, we can enhance our distribution capabilities and more efficiently deliver these very short-lived imaging agents to the clinics and hospitals that need them."

The company's new cyclotron facility in Tampa will be its third in the state, supplementing existing radiopharmaceutical manufacturing sites in Ft. Lauderdale and Orlando. It will be located on the campus of the H. Lee Moffitt Cancer & Research Center, where it will support research and clinical programs in oncology. It will also supply imaging agents to other customers in the greater Tampa area.

The company's new facility in Hartford will house the first commercial cyclotron in the state; and its Louisville cyclotron will be the company's first in Kentucky. The Hartford site will enhance Cardinal Health's ability to serve nuclear pharmacy customers in New England, an area that is also serviced from its Boston and East Rutherford, NJ sites. The Louisville cyclotron will join Cardinal Health's Cincinnati manufacturing facility in servicing central and northern Kentucky. It will also join the company's St. Louis site in servicing western Kentucky.

Cardinal Health operates the largest radiopharmacy network in the United States with more than 150 nuclear pharmacy locations. It is also the largest employer of nuclear pharmacists in the world. The combination of nuclear pharmacy expertise and the size of its network allows Cardinal Health to reach more than 85 percent of all U.S. hospitals within three hours and provide service and clinical expertise to the nuclear medicine community.

About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™ electronic infection surveillance service, VIASYS® respiratory care products and the CareFusion™ patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinalhealth.com.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

Please Send us your Comments.

Printable Story
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2009 DOTmed.com, Inc.
ALL RIGHTS RESERVED